




Instance: composition-en-d99852efa4d4976d99a584078a2ca48c
InstanceOf: CompositionUvEpi
Title: "Composition for karvea Package Leaflet"
Description:  "Composition for karvea Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/97/049/001-003"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd99852efa4d4976d99a584078a2ca48c)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - karvea"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Karvea is and what it is used for </li>
<li>What you need to know before you take Karvea </li>
<li>How to take Karvea </li>
<li>Possible side effects </li>
<li>How to store Karvea </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What karvea is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What karvea is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Karvea belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II 
is a substance produced in the body which binds to receptors in blood vessels causing them to tighten. 
This results in an increase in blood pressure. Karvea prevents the binding of angiotensin-II to these 
receptors, causing the blood vessels to relax and the blood pressure to lower. Karvea slows the 
decrease of kidney function in patients with high blood pressure and type 2 diabetes. </p>
<p>Karvea is used in adult patients 
* to treat high blood pressure (essential hypertension) 
* to protect the kidney in patients with high blood pressure, type 2 diabetes and laboratory 
evidence of impaired kidney function. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take karvea"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take karvea"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Karvea 
* if you are allergic to irbesartan or any other ingredients of this medicine (listed in section 6) 
* if you are more than 3 months pregnant. (It is also better to avoid Karvea in early pregnancy <br />
see pregnancy section) 
* if you have diabetes or impaired kidney function and you are treated with a blood pressure 
lowering medicine containing aliskiren.  </p>
<p>Warning and precautions 
Talk to your doctor before taking Karvea and if any of the following apply to you: 
* if you get excessive vomiting or diarrhoea 
* if you suffer from kidney problems 
* if you suffer from heart problems 
* if you receive Karvea for diabetic kidney disease. In this case your doctor may perform regular 
blood tests, especially for measuring blood potassium levels in case of poor kidney function 
* if you develop low blood sugar levels (symptoms may include sweating, weakness, hunger, 
dizziness, trembling, headache, flushing or paleness, numbness, having a fast, pounding 
heartbeat), particularly if you are being treated for diabetes. 
* if you are going to have an operation (surgery) or be given anaesthetics 
* if you are taking any of the following medicines used to treat high blood pressure: 
 * an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have 
diabetes-related kidney problems. * aliskiren 
Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. 
potassium) in your blood at regular intervals. </p>
<p>See also information under the heading  Do not take Karvea . </p>
<p>You must tell your doctor if you think you are (or might become) pregnant. Karvea is not 
recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it 
may cause serious harm to your baby if used at that stage (see pregnancy section). </p>
<p>Children and adolescents 
This medicinal product should not be used in children and adolescents because the safety and efficacy 
have not yet been fully established. </p>
<p>Other medicines and Karvea 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>Your doctor may need to change your dose and/or to take other precautions: 
 If you are taking an ACE-inhibitor or aliskiren (see also information under the headings  Do not take 
Karvea  and  Warnings and precautions ). </p>
<p>You may need to have blood checks if you take: 
* potassium supplements 
* salt substitutes containing potassium 
* potassium-sparing medicines (such as certain diuretics) 
* medicines containing lithium 
* repaglinide (medication used for lowering blood sugar levels) </p>
<p>If you take certain painkillers, called non-steroidal anti-inflammatory drugs, the effect of irbesartan 
may be reduced. </p>
<p>Karvea with food and drink 
Karvea can be taken with or without food. </p>
<p>Pregnancy and breast-feeding 
Pregnancy 
You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally 
advise you to stop taking Karvea before you become pregnant or as soon as you know you are 
pregnant and will advise you to take another medicine instead of Karvea. Karvea is not recommended 
in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious 
harm to your baby if used after the third month of pregnancy. </p>
<p>Breast-feeding 
Tell your doctor if you are breast-feeding or about to start breast-feeding. Karvea is not recommended 
for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish 
to breast-feed, especially if your baby is newborn, or was born prematurely. </p>
<p>Driving and using machines 
Karvea is unlikely to affect your ability to drive or use machines. However, occasionally dizziness or 
weariness may occur during treatment of high blood pressure. If you experience these, talk to your 
doctor before attempting to drive or use machines. </p>
<p>Karvea contains lactose. If you have been told by your doctor that you have an intolerance to some 
sugars (e.g. lactose), contact your doctor before taking this medicinal product. </p>
<p>Karvea contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is 
to say essentially  sodium-free . </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take karvea"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take karvea"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<p>Method of administration 
Karvea is for oral use. Swallow the tablets with a sufficient amount of fluid (e.g. one glass of water). 
You can take Karvea with or without food. Try to take your daily dose at about the same time each 
day. It is important that you continue to take Karvea until your doctor tells you otherwise. </p>
<ul>
<li>
<p>Patients with high blood pressure 
The usual dose is 150 mg once-a-day (two tablets a day). The dose may later be increased to 
300 mg (four tablets a day) once daily depending on blood pressure response. </p>
</li>
<li>
<p>Patients with high blood pressure and type 2 diabetes with kidney disease 
In patients with high blood pressure and type 2 diabetes, 300 mg (four tablets a day) once daily 
is the preferred maintenance dose for the treatment of associated kidney disease. </p>
</li>
</ul>
<p>The doctor may advise a lower dose, especially when starting treatment in certain patients such as 
those on haemodialysis, or those over the age of 75 years. </p>
<p>The maximal blood pressure lowering effect should be reached 4-6 weeks after beginning treatment. </p>
<p>Use in children and adolescents 
Karvea should not be given to children under 18 years of age. If a child swallows some tablets, contact 
your doctor immediately. </p>
<p>If you take more Karvea than you should 
If you accidentally take too many tablets, contact your doctor immediately. </p>
<p>If you forget to take Karvea 
If you accidentally miss a daily dose, just take the next dose as normal. Do not take a double dose to 
make up for a forgotten dose. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. 
Some of these effects may be serious and may require medical attention. </p>
<p>As with similar medicines, rare cases of allergic skin reactions (rash, urticaria), as well as localised 
swelling of the face, lips and/or tongue have been reported in patients taking irbesartan. If you get any 
of these symptoms or get short of breath, stop taking Karvea and contact your doctor immediately. </p>
<p>The frequency of the side effects listed below is defined using the following convention: 
Very common: may affect more than 1 in 10 people 
Common: may affect up to 1 in 10 people 
Uncommon: may affect up to 1 in 100 people </p>
<p>Side effects reported in clinical studies for patients treated with Karvea were: 
* Very common (may affect more than 1 in 10 people): if you suffer from high blood pressure and 
type 2 diabetes with kidney disease, blood tests may show an increased level of potassium. </p>
<ul>
<li>
<p>Common (may affect up to 1 10 people): dizziness, feeling sick/vomiting, fatigue and blood 
tests may show raised levels of an enzyme that measures the muscle and heart function (creatine 
kinase enzyme). In patients with high blood pressure and type 2 diabetes with kidney disease, 
dizziness when getting up from a lying or sitting position, low blood pressure when getting up 
from a lying or sitting position, pain in joints or muscles and decreased levels of a protein in the 
red blood cells (haemoglobin) were also reported. </p>
</li>
<li>
<p>Uncommon (may affect up to 1 in 100 people): heart rate increased, flushing, cough, diarrhoea, 
indigestion/heartburn, sexual dysfunction (problems with sexual performance), chest pain. </p>
</li>
</ul>
<p>Some undesirable effects have been reported since marketing of Karvea. Undesirable effects where the 
frequency is not known are: feeling of spinning, headache, taste disturbance, ringing in the ears, 
muscle cramps, pain in joints and muscles, decreased number of red blood cells (anaemia   symptoms 
may include tiredness, headaches, being short of breath when exercising, dizziness and looking pale), 
reduced number of platelets, abnormal liver function, increased blood potassium levels, impaired 
kidney function, inflammation of small blood vessels mainly affecting the skin (a condition known as 
leukocytoclastic vasculitis), severe allergic reactions (anaphylactic shock) and low blood sugar levels. 
Uncommon cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been 
reported. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store karvea"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store karvea"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and on the blister after 
EXP. The expiry date refers to the last day of that month. </p>
<p>Do not store above 30 C. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away of medicines you no longer use. These measures will help protect the environment. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Karvea contains 
* The active substance is irbesartan. Each tablet of Karvea 75 mg contains 75 mg irbesartan. 
* The other ingredients are microcrystalline cellulose, croscarmellose sodium, lactose 
monohydrate, magnesium stearate, colloidal hydrated silica, pregelatinized maize starch, and 
poloxamer 188. Please see section 2  Karvea contains lactose . </p>
<p>What Karvea looks like and contents of the pack 
Karvea 75 mg tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one 
side and the number 2771 engraved on the other side. </p>
<p>Karvea 75 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets. Unidose blister packs of 
56 x 1 tablet for delivery in hospitals are also available. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder: 
Sanofi Winthrop Industrie 
82 avenue Raspail 
94250 Gentilly 
France </p>
<p>Manufacturer: 
SANOFI WINTHROP INDUSTRIE 
1, rue de la Vierge 
Ambar s &amp; Lagrave 
F-33565 Carbon Blanc Cedex - France </p>
<p>SANOFI WINTHROP INDUSTRIE 
30-36 Avenue Gustave Eiffel, BP 7F-37071 Tours Cedex 2 - France </p>
<p>For any information about this medicinal product, please contact the local representative of the 
Marketing Authorisation Holder. </p>
<p>Belgi /Belgique/Belgien 
Sanofi Belgium 
T l/Tel: +32 (0)2 710 54 Lietuva 
Swixx Biopharma UAB 
Tel: +370 5 236 91 <br />
Swixx Biopharma EOOD 
 .: +359 (0)2 4942 Luxembourg/Luxemburg 
Sanofi Belgium<br />
T l/Tel: +32 (0)2 710 54 00 (Belgique/Belgien) </p>
<p>esk  republika 
sanofi-aventis, s.r.o. 
Tel: +420 233 086 Magyarorsz g 
SANOFI-AVENTIS Zrt. 
Tel.: +36 1 505 0Danmark 
Sanofi A/S 
Tlf: +45 45 16 70 Malta 
Sanofi S.r.l. 
Tel: +39 02 39394Deutschland 
Sanofi-Aventis Deutschland GmbH 
Tel: 0800 52 52 Tel. aus dem Ausland: +49 69 305 21 Nederland 
Sanofi B.V. 
Tel: +31 20 245 4Eesti 
Swixx Biopharma O<br />
Tel: +372 640 10 Norge 
sanofi-aventis Norge AS 
Tlf: +47 67 10 71 <br />
Sanofi-Aventis   <br />
 : +30 210 900 16  sterreich 
sanofi-aventis GmbH 
Tel: +43 1 80 185   0 </p>
<p>Espa a 
sanofi-aventis, S.A. 
Tel: +34 93 485 94 Polska 
sanofi-aventis Sp. z o.o. 
Tel.: +48 22 280 00 France 
Sanofi Winthrop Industrie 
T l: 0 800 222 Appel depuis l tranger: +33 1 57 63 23 Portugal 
Sanofi - Produtos Farmac uticos, Lda 
Tel: +351 21 35 89 Hrvatska 
Swixx Biopharma d.o.o. 
Tel: +385 1 2078 Rom nia 
Sanofi Romania SRL 
Tel: +40 (0) 21 317 31 Ireland 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +353 (0) 1 403 56 Slovenija 
Swixx Biopharma d.o.o. 
Tel: +386 1 235 51  sland 
Vistor hf. 
S mi: +354 535 7Slovensk  republika 
Swixx Biopharma s.r.o. 
Tel: +421 2 208 33 Italia 
Sanofi S.r.l. 
Tel: 800 536Suomi/Finland 
Sanofi Oy 
Puh/Tel: +358 (0) 201 200 <br />
C.A. Papaellinas Ltd. 
 : +357 22 741Sverige 
Sanofi AB 
Tel: +46 (0)8 634 50 Latvija 
Swixx Biopharma SIA 
Tel: +371 6 616 47 United Kingdom (Northern Ireland) 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +44 (0) 800 035 2This leaflet was last revised in </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-d99852efa4d4976d99a584078a2ca48c
InstanceOf: CompositionUvEpi
Title: "Composition for karvea Package Leaflet"
Description:  "Composition for karvea Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/97/049/001-003"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd99852efa4d4976d99a584078a2ca48c)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - karvea"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Karvea 
3. Sådan skal du tage Karvea 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p> </div>"""   
          

* section[=].section[+]
  * title =  "1. What karvea is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What karvea is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Karvea tilhører en medicingruppe, der kaldes angiotensin-II receptorantagonister. Angiotensin-II er et 
stof, der produceres i kroppen, og som binder sig til receptorer i blodårerne og får dem til at trække sig 
sammen. Dette medfører, at blodtrykket øges. Karvea forebygger at angiotensin-II binder sig til disse 
receptorer. Derved afslappes blodårerne, og blodtrykket falder. Karvea mindsker faldende 
nyrefunktion hos patienter med forhøjet blodtryk og type 2 diabetes (sukkersyge). </p>
<p>Karvea anvendes til voksne patienter </p>
<ul>
<li>
<p>til at behandle forhøjet blodtryk (hypertension) </p>
</li>
<li>
<p>til at beskytte nyrerne hos patienter med for højt blodtryk, type 2 diabetes og blodprøver, der viser 
nedsat nyrefunktion. </p>
</li>
</ul> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take karvea"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take karvea"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Karvea: </p>
<ul>
<li>
<p>hvis du er overfølsom (allergisk) over for irbesartan eller et af de øvrige indholdsstoffer i 
Karvea (angivet i punkt 6). </p>
</li>
<li>
<p>hvis du er længere end 3 måneder henne i din graviditet. (Det er også bedre at lade være med 
at tage Karvea i begyndelsen af graviditeten - se afsnittet om graviditet) </p>
</li>
<li>
<p>hvis du har diabetes eller nedsat nyrefunktion, og du bliver behandlet med et lægemiddel, 
der sænker blodtrykket, som indeholder aliskiren  </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, før du tager Karvea, hvis noget af det følgende gælder for dig: </p>
<ul>
<li>
<p>hvis du får hyppig opkastning eller diarré </p>
</li>
<li>
<p>hvis du lider af nyreproblemer </p>
</li>
<li>
<p>hvis du lider af hjerteproblemer </p>
</li>
<li>
<p>hvis du får Karvea for diabetisk nyresygdom. I dette tilfælde kan lægen tage regelmæssige 
blodprøver med særlig henblik på at måle kaliumniveauet i blodet, hvis nyrefunktionen er 
nedsat </p>
</li>
<li>
<p>hvis du udvikler lavt blodsukkerniveau (symptomerne kan inkludere svedtendens, svaghed, 
sult, svimmelhed, skælven, hovedpine, rødmen eller bleghed, følelsesløshed, hurtige og 
hamrende hjerteslag), især hvis du er i behandling for diabetes </p>
</li>
<li>
<p>hvis du skal opereres eller bedøves </p>
</li>
<li>
<p>hvis du tager en af følgende lægemidler, der anvendes til at behandle forhøjet blodtryk: * en ACE-hæmmer (f.eks. enalapril, lisinopril, remipril) især hvis du har 
nyreproblemer, der skyldes diabetes. * Aliskiren. </p>
</li>
</ul>
<p>Din læge vil måske regelmæssigt kontrollere din nyrefunktion, dit blodtryk og mængden af 
elektrolytter (f.eks. kalium) i dit blod.  </p>
<p>Se også information under "Tag ikke Karvea". </p>
<p>Du skal fortælle det til din læge, hvis du tror du er gravid eller planlægger at blive gravid. Karvea bør 
ikke bruges tidligt i graviditeten og du må ikke tage Karvea, hvis du er længere end 3 måneder henne i 
din graviditet, da det kan skade dit barn alvorligt, hvis det bruges i den periode (se afsnittet om 
graviditet). </p>
<p>Børn og unge<br />
Dette lægemiddel bør ikke anvendes til børn og unge, da sikkerhed og virkning ikke er blevet 
fuldstændig klarlagt. </p>
<p>Brug af anden medicin sammen med Karvea 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for 
nylig.  </p>
<p>Din læge kan blive nødt til at ændre din dosis og/eller tage andre forholdsregler: 
Hvis du tager en ACE-hæmmer eller aliskiren (se også information under "Tag ikke Karvea" og 
"Advarsler og forsigtighedsregler").  </p>
<p>Det kan være nødvendigt at tage blodprøver, hvis du tager: </p>
<ul>
<li>
<p>kaliumtilskud </p>
</li>
<li>
<p>salterstatninger, der indeholder kalium </p>
</li>
<li>
<p>kaliumsparende medicin (som visse vanddrivende lægemidler) </p>
</li>
<li>
<p>medicin, der indeholder lithium </p>
</li>
<li>
<p>repaglinid (medicin, der anvendes til at sænke blodsukkerniveauet). </p>
</li>
</ul>
<p>Hvis du tager en bestemt slags smertestillende medicin, der kaldes non-steroide anti-inflammatoriske 
lægemidler, kan virkningen af irbesartan nedsættes. </p>
<p>Brug af Karvea sammen med mad og drikke 
Karvea kan tages med og uden mad. </p>
<p>Graviditet og amning 
Graviditet 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du tager Karvea.<br />
Din læge vil normalt anbefale, at du stopper med at tage Karvea, inden du bliver gravid, eller så snart 
du ved, at du er gravid, og anbefale, at du tager anden medicin i stedet for Karvea. Karvea frarådes 
tidligt i graviditeten, og du må ikke tage det, hvis du er længere end 3 måneder henne i graviditeten, da 
det kan skade dit barn alvorligt, hvis du tager det efter tredje måned af graviditeten. </p>
<p>Amning 
Fortæl det til lægen, hvis du ammer eller skal til at amme. Karvea anbefales ikke til ammende mødre, 
og lægen vil sædvanligvis vælge en anden behandling til dig, hvis du ønsker at amme dit barn, især 
hvis dit barn er nyfødt eller født for tidligt. </p>
<p>Trafik- og arbejdssikkerhed 
Karvea påvirker sandsynligvis ikke din evne til at køre bil eller betjene maskiner.Men man kan opleve 
svimmelhed eller træthed, når man behandles for forhøjet blodtryk. Hvis du bliver svimmel eller træt, 
skal du kontakte lægen, inden du kører bil eller betjener maskiner. </p>
<p>Karvea indeholder lactose 
Kontakt lægen, før du tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse 
sukkerarter. </p>
<p>Karvea indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take karvea"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take karvea"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid Karvea nøjagtigt efter lægen anvisning. Er du i tvivl, så spørg lægen eller på apoteket. </p>
<p>Sådan tages tabletterne 
Karvea skal tages gennem munden. Tabletterne skal synkes med en tilstrækkelig mængde væske (for 
eksempel 1 glas vand). Du kan tage Karvea med eller uden mad. Prøv at tage medicinen på ca. samme 
tidspunkt hver dag. Det er vigtigt, at du fortsætter med at tage Karvea, indtil lægen siger du kan 
stoppe. </p>
<ul>
<li>
<p>Patienter med højt blodtryk 
Den sædvanlige dosis er 150 mg 1 gang dagligt (to tabletter dagligt). Dosis kan senere øges til 
300 mg 1 gang dagligt (fire tabletter dagligt) afhængig af blodtryksmålingerne. </p>
</li>
<li>
<p>Patienter med højt blodtryk og type 2 diabetes med nyresygom 
Hos patienter med højt blodtryk og type 2 diabetes er 300 mg 1 gang dagligt (fire tabletter 
dagligt) den foretrukne vedligeholdelsesdosis til behandling af ledsagende nyresygdom. </p>
</li>
</ul>
<p>Lægen kan anbefale en lavere dosis, specielt til patienter, som bliver behandlet med hæmodialyse 
eller til ældre patienter over 75 år. </p>
<p>Den maksimale blodtryksnedsættende virkning skal være nået 4-6 uger efter behandlingsstart. </p>
<p>Børn og unge må ikke få Karvea<br />
Karvea må ikke gives til børn under 18 år. Hvis et barn sluger en eller flere tabletter, skal du straks 
kontakte lægen. </p>
<p>Hvis du har taget for mange Karvea 
Hvis du ved et uheld har taget for mange tabletter, skal du omgående kontakte lægen. </p>
<p>Hvis du har glemt at tage Karvea 
Hvis du har glemt at tage en dosis, skal du blot tage den næste til sædvanlig tid. Tag ikke dobbeltdosis 
som erstatning for den glemte dosis. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.  </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. 
Nogle af disse bivirkninger kan være alvorlige og kan kræve medicinsk behandling. </p>
<p>Som ved anden medicin af samme type, er der hos patienter, der har modtaget behandling med 
irbesartan, rapporteret sjældne tilfælde af allergiske hudreaktioner (udslæt, nældefeber) samt 
opsvulmet ansigt, læber og/eller tunge. Hvis du får et eller flere af disse symptomer eller får åndenød, 
skal du holde op med at tage Karvea og straks søge lægehjælp. </p>
<p>Hyppigheden af nedenstående bivirkninger er angivet på følgende måde: 
Meget almindelig: kan påvirke flere end 1 ud af 10 patienter<br />
Almindelig: kan påvirke op til 1 ud af 10 patienter 
Ikke almindelig: kan påvirke op til 1 ud af 100 patienter </p>
<p>Følgende bivirkninger blev indberettet i kliniske forsøg med patienter, der fik Karvea: </p>
<ul>
<li>
<p>Meget almindelig (kan påvirke flere end 1 ud af 10 patienter):  hvis du har højt blodtryk og type 2 
diabetes med nyresygdom, kan blodprøver vise, at du har for meget kalium i blodet. </p>
</li>
<li>
<p>Almindelig (kan påvirke op til 1 ud af 10 patienter): svimmelhed, kvalme/opkastning, træthed og 
blodprøver, der viser en forhøjet mængde af et enzym, der måler muskel- og hjertefunktionen 
(kreatinin-kinase-enzym).Der er hos patienter med forhøjet blodtryk og type 2 diabetes med 
nyresygdom også indberettet svimmelhed, når man rejser sig op fra liggende eller siddende 
stilling, lavt blodtryk når man rejser sig op fra liggende eller siddende stilling, led- og 
muskelsmerter og en nedsat mængde protein i de røde blodlegemer (hæmoglobin). </p>
</li>
<li>
<p>Ikke almindelig (kan påvirke op til 1 ud af 100 patienter): hurtig hjerterytme, rødme, hoste, diarré, 
fordøjelsesbesvær/halsbrand, seksuelle problemer, brystsmerter. </p>
</li>
</ul>
<p>Der er indberettet bivirkninger efter markedsføring af Karvea. Bivirkninger, hvor hyppigheden ikke er 
kendt, er: følelse af, at omgivelserne kører rundt, hovedpine, smagsforstyrrelser, ringen for ørerne, 
muskelkramper, led- og muskelsmerter, nedsat antal røde blodlegemer (blodmangel - symptomerne 
kan inkludere træthed, hovedpine, stakåndethed under motion, svimmelhed og bleghed), nedsat antal 
blodplader, unormal leverfunktion, forhøjet mængde af kalium i blodet, nedsat nyrefunktion, 
betændelseslignende tilstand i de små blodkar, der primært påvirker huden (en tilstand der kaldes 
leukocytoklastisk vaskulitis), alvorlige allergiske reaktioner (anafylaktisk shock) samt lavt 
blodsukkerniveau. Der er i sjældne tilfælde også indberettet gulsot (gulfarvning af huden og/eller det 
hvide i øjnene). </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store karvea"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store karvea"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og blisterpakningen efter Exp. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 30°C. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Karvea indeholder: </p>
<ul>
<li>
<p>Aktivt stof: irbesartan. Hver Karvea-tablet 75 mg indeholder 75 mg irbesartan. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: lactosemonohydrat, mikrokrystallinsk cellulose, croscarmellosenatrium, 
magnesiumstearat, kolloid silica, prægelatineret majsstivelse, poloaxamer 188. Se punkt 2 "Aprovel indeholder lactose" </p>
</li>
</ul>
<p>Udseende og pakningstørrelser 
Karvea 75 mg tabletter er hvide til mathvide, bikonvekse og ovale med et hjerte præget på den ene 
side og nummeret 2771 på den anden side. </p>
<p>Karvea 75 mg tabletter leveres i blisterpakninger af 14, 28, 56 eller 98 tabletter. Der fås også 
enkeltdosisblisterpakninger med 56 x 1 tablet til hospitalsbrug. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaveren af markedsføringstilladelsen: 
Sanofi Winthrop Industrie 
82 avenue Raspail 
94250 Gentilly 
Frankrig </p>
<p>Fremstiller: 
SANOFI WINTHROP INDUSTRIE 
1, rue de la Vierge 
Ambarès &amp; Lagrave 
F-33565 Carbon Blanc Cedex - Frankrig </p>
<p>SANOFI WINTHROP INDUSTRIE 
30-36 Avenue Gustave Eiffel, BP 7F-37071 Tours Cedex 2 - Frankrig </p>
<p>Hvis du vil have yderligere oplysninger om Karvea, skal du henvende dig til den lokale repræsentant 
for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Sanofi Belgium 
Tél/Tel: +32 (0)2 710 54<br />
Lietuva 
Swixx Biopharma UAB 
Tel: +370 5 236 91<br />
България 
Swixx Biopharma EOOD 
Тел.: +359 (0)2 4942<br />
Luxembourg/Luxemburg 
Sanofi Belgium<br />
Tél/Tel: +32 (0)2 710 54 00 (Belgique/Belgien) </p>
<p>Česká republika 
sanofi-aventis, s.r.o. 
Tel: +420 233 086<br />
Magyarország 
SANOFI-AVENTIS Zrt. 
Tel.: +36 1 505 0 
Danmark 
Sanofi A/S 
Tlf: +45 45 16 70<br />
Malta 
Sanofi S.r.l. 
Tel: +39 02 39394 </p>
<p>Deutschland 
Sanofi-Aventis Deutschland GmbH 
Tel: 0800 52 52 Tel. aus dem Ausland: +49 69 305 21<br />
Nederland 
Sanofi B.V. 
Tel: +31 20 245 4 
Eesti 
Swixx Biopharma OÜ 
Tel: +372 640 10<br />
Norge 
sanofi-aventis Norge AS 
Tlf: +47 67 10 71<br />
Ελλάδα 
Sanofi-Aventis Μονοπρόσωπη AEBE 
Τηλ: +30 210 900 16<br />
Österreich 
sanofi-aventis GmbH 
Tel: +43 1 80 185 - 0 </p>
<p>España 
sanofi-aventis, S.A. 
Tel: +34 93 485 94<br />
Polska 
sanofi-aventis Sp. z o.o. 
Tel.: +48 22 280 00<br />
France 
Sanofi Winthrop Industrie 
Tél:<br />
0 800 222 Appel depuis l’étranger : +33 1 57 63 23<br />
Portugal 
Sanofi - Produtos Farmacêuticos, Lda 
Tel: +351 21 35 89<br />
Hrvatska 
Swixx Biopharma d.o.o. 
Tel: +385 1 2078 România 
Sanofi Romania SRL 
Tel: +40 (0) 21 317 31<br />
Ireland 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +353 (0) 1 403 56<br />
Slovenija 
Swixx Biopharma d.o.o. 
Tel: +386 1 235 51<br />
Ísland 
Vistor hf. 
Sími: +354 535 7 
Slovenská republika 
Swixx Biopharma s.r.o. 
Tel: +421 2 208 33<br />
Italia 
Sanofi S.r.l. 
Tel: 800.536 
Suomi/Finland 
Sanofi Oy 
Puh/Tel: +358 (0) 201 200<br />
Κύπρος 
C.A. Papaellinas Ltd. 
Τηλ: +357 22 741 
Sverige 
Sanofi AB 
Tel: +46 (0)8 634 50<br />
Latvija 
Swixx Biopharma SIA 
Tel: +371 6 616 47<br />
United Kingdom (Northern Ireland) 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +44 (0) 800 035 2 
Denne indlægsseddel blev senest ændret  </p>
<p>Du kan finde yderligere information om Karvea på Det Europæiske Lægemiddelagenturs hjemmeside </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-d99852efa4d4976d99a584078a2ca48c
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for karvea Package Leaflet for language en"
Description: "ePI document Bundle for karvea Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-d99852efa4d4976d99a584078a2ca48c"
* entry[0].resource = composition-en-d99852efa4d4976d99a584078a2ca48c

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpd99852efa4d4976d99a584078a2ca48c"
* entry[=].resource = mpd99852efa4d4976d99a584078a2ca48c
                            
                    
Instance: bundlepackageleaflet-da-d99852efa4d4976d99a584078a2ca48c
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for karvea Package Leaflet for language da"
Description: "ePI document Bundle for karvea Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-d99852efa4d4976d99a584078a2ca48c"
* entry[0].resource = composition-da-d99852efa4d4976d99a584078a2ca48c

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpd99852efa4d4976d99a584078a2ca48c"
* entry[=].resource = mpd99852efa4d4976d99a584078a2ca48c
                            
                    



Instance: mpd99852efa4d4976d99a584078a2ca48c
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Karvea 75 mg tablets."
Description: "Karvea 75 mg tablets."
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/97/049/001-003"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Karvea 75 mg tablets."
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: d99852efa4d4976d99a584078a2ca48cListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "karvea"

* status = #current
* mode = #working

* title = "List of all ePIs associated with karvea"

* subject = Reference(mpd99852efa4d4976d99a584078a2ca48c)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#karvea "karvea"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-d99852efa4d4976d99a584078a2ca48c) // karvea en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-d99852efa4d4976d99a584078a2ca48c) // karvea da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-d99852efa4d4976d99a584078a2ca48c
InstanceOf: List

* insert d99852efa4d4976d99a584078a2ca48cListRuleset
    